A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation by Mathias, Susan D et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Health and Quality of Life Outcomes
Open Access Research
A disease-specific measure of health-related quality of life for use in 
adults with immune thrombocytopenic purpura: Its development 
and validation
Susan D Mathias*1, James B Bussel2, James N George3, Robert McMillan4, 
Gary J Okano5 and Janet L Nichol5
Address: 1Ovation Research Group, 188 Embarcadero, Suite 200, San Francisco, CA 94105, USA, 2New York Presbyterian Hospital/Weill Cornell 
Medical Center, 525 East 68th Street, New York, NY 10021, USA, 3University of Oklahoma Health Sciences Center, P.O. Box 26901, Oklahoma 
City, OK 73190, USA, 4The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA and 5Amgen, Inc. One Amgen Center 
Drive, MS: 28-3-A, Thousand Oaks, CA 91320-1799, USA
Email: Susan D Mathias* - smathias@ovation.org; James B Bussel - jbussel@med.cornell.edu; James N George - james-george@ouhsc.edu; 
Robert McMillan - mcmillan@scripps.edu; Gary J Okano - gokano@amgen.com; Janet L Nichol - jnichol@amgen.com
* Corresponding author    
Abstract
Background: No validated disease-specific measures are available to assess health-related quality of life (HRQoL) in
adult subjects with immune thrombocytopenic purpura (ITP). Therefore, we sought to develop and validate the ITP-
Patient Assessment Questionnaire (ITP-PAQ) for adult subjects with ITP.
Methods: Information from literature reviews, focus groups with subjects, and clinicians were used to develop 50 ITP-
PAQ items. Factor analyses were conducted to develop the scale structure and reduce the number of items. The final
44-item ITP-PAQ, which includes ten scales [Symptoms (S), Bother-Physical Health (B), Fatigue/Sleep (FT), Activity (A),
Fear (FR), Psychological Health (PH), Work (W), Social Activity (SA), Women's Reproductive Health (RH), and Overall
(QoL)], was self-administered to adult ITP subjects at baseline and 7–10 days later. Test-retest reliability, internal
consistency reliability, construct and known groups validity of the final ITP-PAQ were evaluated.
Results: Seventy-three subjects with ITP completed the questionnaire twice. Test-retest reliability, as measured by the
intra-class correlation, ranged from 0.52–0.90. Internal consistency reliability was demonstrated with Cronbach's alpha
for all scales above the acceptable level of 0.70 (range: 0.71–0.92), except for RH (0.66). Construct validity, assessed by
correlating ITP-PAQ scales with established measures (Short Form-36 v.1, SF-36 and Center for Epidemiologic Studies
Depression Scale, CES-D), was demonstrated through moderate correlations between the ITP-PAQ SA and SF-36 Social
Function scales (r = 0.67), and between ITP-PAQ PH and SF-36 Mental Health Scales (r = 0.63). Moderate to strong inter-
scale correlations were reported between ITP-PAQ scales and the CES-D, except for the RH scale. Known groups
validity was evaluated by comparing mean scores for groups that differed clinically. Statistically significant differences (p
< 0.01) were observed when subjects were categorized by treatment status [S, FT, B, A, PH, and QoL, perceived
effectiveness of ITP treatment [S], and time elapsed since ITP diagnosis [PH].
Conclusion: Results provide preliminary evidence of the reliability and validity of the ITP-PAQ in adult subjects with
ITP. Further work should be conducted to assess the responsiveness and to estimate the minimal clinical important
difference of the ITP-PAQ to more fully understand the impact of ITP and its treatments on HRQoL.
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Background
Immune thrombocytopenic purpura (ITP) is a disorder
characterized by autoimmune-mediated platelet destruc-
tion and suboptimal platelet production [1-3] that results
in a decrease in the number of circulating platelets and
increases the risk of bleeding events. The estimated preva-
lence rate for ITP in the United States is 9.5/100,000 [4].
Adult women are disproportionately affected by the disor-
der, with a female to male ratio of nearly two to one [5].
The disorder rarely remits spontaneously in adult subjects
[1]. The mortality rate is relatively low (< 1%) [6] in adults
less than 65 years of age. Morbidity increases above age
65, primarily as a result of an increase in age-related major
bleeding events [7].
Initial therapy for ITP consists of some combination of
glucocorticoids, intravenous immune globulin (IVIg) or
anti-D [8]. Splenectomy is often considered if these thera-
pies fail. Approximately two-thirds of patients treated
with splenectomy achieve a sustained remission [1,5,9].
Patients who fail splenectomy are treated with a wide vari-
ety of agents including corticosteroids, danazol, and
chemotherapeutic agents. Morbidity and mortality in
these refractory patients are substantial [1,6,8].
Patient-reported outcomes (PRO), including health-
related quality of life (HRQoL) measures, are critical com-
ponents for evaluating and understanding treatment
effects from the subject's perspective. The Food and Drug
Administration (FDA) indicates that PRO measures are
important to assess because they may: 1) detect treatment
effects known only to the subject; 2) understand the sub-
ject's perspective regarding treatment effect; or 3) provide
information not included in a clinician's subject notes
[10]. Furthermore, the Committee for Medicinal Products
for Human Use of the European Medicines Agency defines
HRQoL as "the subject's subjective perception of the
impact of his disease and its treatment(s) on his daily life,
physical, psychological and social functioning and well-
being" [11].
Currently, limited data are available on the assessment of
the impact of symptoms in adult subjects with ITP. Symp-
toms of ITP, such as spontaneous bruising, menorrhagia,
mucosal bleeding and prolonged bleeding with injury,
may significantly affect HRQoL in ITP subjects [12]. Treat-
ments for chronic ITP can also be associated with substan-
tial side effects [5,8]. In addition, subjects who are
resistant to current therapies are likely to experience an
even greater decrement to their HRQoL than responders
to treatment. Thus, restoring and/or maintaining quality
of life should be an important goal of treatment. While
the primary markers for ITP include hematologic meas-
ures such as platelet counts, clinical measures typically do
not assess a subject's functioning and well-being. There-
fore, subjects and physicians may want to weigh the
impact of ITP therapies on HRQoL endpoints when mak-
ing treatment decisions.
Previously, no validated disease-specific measures were
available to evaluate quality of life in adult ITP subjects;
however, two disease-specific HRQoL questionnaires
have been developed for use in children with ITP [13,14].
Thus, we sought to develop a questionnaire that would be
appropriate to assess the impact of ITP symptoms and its
treatments on HRQoL in adult subjects. The objective of
this current manuscript is to describe the development
and initial validation of a newly developed HRQoL ques-
tionnaire for use in adult subjects with ITP.
Methods
Overview
A newly developed questionnaire, which assesses issues of
importance to ITP subjects, was developed based on avail-
able published literature, existing questionnaires, expert
clinical opinion, and input from subjects with ITP.
Subjects and Procedures
To develop the questionnaire, three focus groups with ITP
subjects were conducted in geographically diverse loca-
tions (San Diego, CA, New York, NY, and Oklahoma City,
OK). Each of the three sites recruited a convenience sam-
ple of five to eight ITP subjects who were being treated on
an outpatient basis. To be eligible, subjects were required
to have active disease and be ≥ 18 years of age. Although
platelet count data were not required for participation in
the focus groups, clinicians at each site considered the
subjects to have active disease, usually an indication that
platelet levels have dropped below 120 × 109L and the
subject requires treatment and/or more frequent monitor-
ing. In total, 23 ITP subjects participated in the focus
groups after providing their informed consent.
To validate the questionnaire, a convenience sample of
subjects was recruited from the same three clinical sites in
New York, NY, Oklahoma City, OK, and La Jolla, CA. Sub-
jects were eligible if they were ≥ 18 years of age, had active
disease, and were willing to complete a self-administered
questionnaire at two time points. Target enrollment was
roughly 72 subjects (24 subjects from each site).
The study protocol was approved by a local institutional
review board at each site and was carried out in accord-
ance with Good Clinical Practice and International Con-
ference on Harmonization guidelines and the Declaration
of Helsinki. Written informed consent was obtained from
each subject prior to enrollment.Health and Quality of Life Outcomes 2007, 5:11 http://www.hqlo.com/content/5/1/11
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Creation of Questionnaire/Item Selection
A trained moderator led all focus groups using a detailed
discussion guide. Subjects discussed their ITP history,
treatment, ITP symptoms, and the impact of ITP on daily
activities. Each focus group lasted approximately three
hours, and subjects were provided with an honorarium
for their time. Following the focus group session, all sub-
jects completed a questionnaire which included the SF-36
v1 [15] and ITP-specific questions. The ITP-specific items
were developed based on clinical input [12,16-18]. The
ITP-specific items assessed the impact of ITP on the sub-
ject's overall quality of life, relationships, ability to sleep,
menstruation/gynecological history, and sexual activity.
The ITP-specific questions also assessed the subject's
response to ITP treatments and any side effects. Tran-
scripts of the focus groups were summarized and reviewed
by the study team. The initial draft of the ITP Subject
Assessment Questionnaire (ITP-PAQ) was developed after
reviewing information from the literature searches, exist-
ing questionnaires, expert opinion, focus group tran-
scripts, and the questionnaire responses from the focus
group subjects.
The initial ITP-PAQ consisted of 50 items that assesses the
impact of ITP in the areas of physical health, mental
health, work, social activity, reproductive health (relevant
for women only), and overall quality of life. Factor analy-
ses were conducted which yielded six unique domains.
The impact of ITP on physical health was measured by
four scales that evaluated ITP-related symptoms, Fatigue/
Sleep, Bother-Physical Health, and Activity. Its impact on
mental health was measured by two scales that evaluated
psychological distress and fear. A copy of the question-
naire can be obtained by contacting Janet L. Nichol and
sample items are included Table 2.
Statistical Analyses
A validation study was conducted to evaluate the psycho-
metric properties of the newly developed ITP-PAQ ques-
tionnaire so that it could be used to measure the impact of
ITP in adult subjects in future studies. Standard psycho-
metric methods were used to evaluate the reliability and
validity of the questionnaire [19,20].
Eligible subjects completed the baseline questionnaire at
the site or by mail after providing telephone consent. An
informed consent form and baseline questionnaire was
mailed to those subjects who gave their initial consent via
telephone. These completed documents were returned by
mail to the investigators. At follow up, each subject was
mailed the same questionnaire and asked to complete it a
second time (for evaluating test-retest reliability) approx-
imately two weeks later. Additionally, subjects completed
the SF-36 and the CES-D[21] for validation purposes at
both assessments. Demographic and clinical characteris-
tics were also solicited in order to more fully describe the
study population. Each study subject received an honorar-
ium for completing the questionnaires.
Scale creation and confirmatory factor analysis
Confirmatory factor analyses were conducted to test the
hypothesized structure of the scales. Two models using
LISREL version 8 were tested [22]. The first model con-
sisted of all 50 HRQoL items and 10 factors, whereas the
second model consisted of a subset of the 50-item corre-
lation matrix. Only women respond to the six items com-
prising the Reproductive Health scale, so the items were
not included in the second LISREL model to avoid estima-
tion biases. The remaining 44 items were analyzed. Model
fit was evaluated using the goodness-of-fit (GFI), the
normed fit index (NFI), the non-normed fit index (NNFI),
the comparative fit index (CIF), and the root mean square
error of approximation (RMSEA). For the confirmatory
models, index values greater than 0.95 indicate better fit,
and RMSEA values less than 0.05 are considered evidence
of adequate fit [23].
Reliability and stability
Two forms of reliability were assessed: test-retest reliabil-
ity and internal consistency reliability. Test-retest reliabil-
ity, a measure of the degree to which the questionnaire
yields stable scores over a short period of time (assuming
there is no underlying change), was measured by the
intra-class correlation coefficient (ICC) [24,25]. An ICC of
≥ 0.70 was considered acceptable [26].
Internal consistency reliability, the extent to which items
within each scale correlate with each other to form a
multi-item scale, was assessed using Cronbach's alpha
[25,27]. Data from both assessments were used to evalu-
ate internal consistency reliability. An alpha coefficient of
≥ 0.70 was considered acceptable, which is the commonly
accepted minimal standard for reliability coefficients
endorsed by the Scientific Advisory Committee of the
Medical Outcomes Trust [26].
Construct Validity
Construct validity was assessed by examining the inter-
scale correlations between the ITP-PAQ and the CES-D
and the ITP-PAQ with the SF-36 and by examining the
strength of the within ITP-PAQ scale correlations [25,28].
For both inter-scale and intra-scale correlations, we made
a priori hypotheses about the directionality and magni-
tude of the correlation and observed the extent to which
hypothesized relationships held. For example, we hypoth-
esized that the scales of the ITP-PAQ would be negatively
correlated with the CES-D and positively correlated with
those of the SF-36. We expected the Pearson correlations
to be moderate in size.Health and Quality of Life Outcomes 2007, 5:11 http://www.hqlo.com/content/5/1/11
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Known Groups
Known groups validity evaluates the ability of the meas-
ure to discriminate between groups known to be clinically
different [28]. We only collected patient-reported infor-
mation using the questionnaire and did not collect clini-
cal information such as platelet counts. Therefore, the
following four criteria were identified as proxies for sever-
ity:
￿ Currently on treatment
￿ Splenectomy status
￿ Subjects' self-perception of the effectiveness of current
medication
￿ Length of time since diagnosis
It was hypothesized that subjects not being treated, who
did not have a splenectomy, who perceived their medica-
tion to be more effective, and who had been diagnosed
with ITP for a longer time would be healthier and there-
fore report higher HRQoL scores. In contrast, subjects on
any treatment, who had received a splenectomy, who per-
ceived their medication to be less effective, and who were
diagnosed more recently would report worse HRQoL. In
addition, subjects were also categorized by gender. Sub-
jects were categorized into two groups for each of the anal-
yses: female vs. male, intact spleen vs. removed spleen,
currently on ITP treatment vs. not currently on ITP treat-
ment, subject's perception of the effectiveness of their cur-
rent ITP medication (extremely/moderately effective vs.
not at all effective), and ITP diagnosis less than one year
ago vs. ITP diagnosis more than one year ago.
Results
Demographics and clinical characteristics
Table 1 describes the demographic and clinical character-
istics of the 73 subjects included in the validation analy-
ses. The majority were female (77%) and Caucasian
(84%). The mean age was 45 years (SD = 15.7), and most
of the subjects had been diagnosed with ITP for at least
five years (57%). Fifty-two percent of the subjects reported
that they were currently taking medications for their ITP.
Furthermore, 58% indicated that they had a splenectomy.
Among the 42 subjects who had a splenectomy, 55%
reported that the removal of their spleen did not cure their
ITP. With one exception, the remaining subjects did not
provide a response.
Confirmatory factor analysis
The first confirmatory factor analysis of the 50-item and
ten factors model converged in 28 iterations. However,
neither the inter-item correlation matrix nor the inter-fac-
tor correlation matrix was positive-definite, which sug-
gests that the proposed model is wrong for the data or the
data are inadequate for the model[22]. The chi-square
value of the model was 316.64 with 1129 degrees of free-
dom (p = 1.0), which does not support the hypothesized
scale structure of the initial ITP-PAQ. The confirmatory
analysis of this LISREL model indicate that computing
domain scores for the Physical Health and Mental Health
domains is not appropriate for the ITP-PAQ.
The second LISREL model was analyzed to confirm the
scale structure, excluding the Reproductive Health scale.
For this model, 126 parameters were estimated: 46 factor
loadings, 44 error terms, and 36 inter-factor correlations.
The model converged in 39 iterations, with a chi-square
value of 1043.10 with 864 degrees of freedom (p < 0.01).
The Goodness of Fit Index (GFI), Normed Fit Index (NFI),
Non-normed Fit Index (NNFI), and Comparative Fit
Index (CFI) was 0.60, 0.63, 0.91, and 0.92, respectively,
and the RMSEA was 0.05 [90% CI, 0.04–0.065]. Further-
more, the inter-factor correlations ranged form 0.33
between the Symptoms and Work scales to 0.96 between
the Bother-Physical Health and Overall QoL scales.
In addition to the confirmatory factor analyses, Cron-
bach's alphas and item-to-total correlations were used for
item reduction. Items with low factor loadings and item-
to-total correlations that reduced the internal consistency
were eliminated. Although initial factor analyses identi-
fied six domains for future use, the final version of the
ITP-PAQ contained 44 items that included the following
ten scales: Symptoms, Bother-Physical Health, Fatigue/
Sleep, Activity, Fear, Psychological Health, Work, Social
Activity, Women's Reproductive Health, and Overall QoL.
Table 2 provides information on the number of items,
item variability and sample items from each scale of the
questionnaire. Each scale is scored from 0 to 100, with
higher scores representing better quality of life.
Test-retest reliability
Of the 73 subjects who completed the first administration
of the questionnaire, most of the subjects completed the
second questionnaire within a 15-day period (75%), dur-
ing which subjects were expected to remain clinically sta-
ble. However, 20% of the 73 subjects completed the
questionnaire within three weeks following the first
administration. The remaining 5% of subjects completed
it between four and nine weeks after the first "test." ICC's
were computed for the entire sample (n = 73) and for a
sub-sample of respondents who completed the second
questionnaire within three weeks (n = 69). With the
exception of the Bother-Physical Health and Activity
scales, all scales had acceptable test-retest reliability (ICC
≥ 0.70) as measured by the ICC (Table 3). For the entire
sample, ICC values ranged from 0.52–0.90, while ICC val-
ues for the sub-sample ranged from 0.56–0.89.Health and Quality of Life Outcomes 2007, 5:11 http://www.hqlo.com/content/5/1/11
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Internal consistency reliability
Internal consistency reliability, measured by Cronbach's
alpha, ranged from 0.66 to 0.92 (Table 3). With the excep-
tion of the Reproductive Health scale, Cronbach's alpha
coefficients exceeded the acceptable level of 0.70. Cron-
bach's alpha for the Symptoms, Bother-Physical Health,
Fatigue/Sleep, and Activity scales ranged from 0.71–0.89,
while Cronbach's alpha for the Psychological Health and
Fear scales ranged from 0.87–0.92. Additionally, Cron-
bach's alphas for the Social Activity, Work, Reproductive
Health, and Overall QoL scales were 0.72, 0.86, 0.66, and
0.89, respectively.
Construct validity
Table 4 displays the results of inter-scale Pearson correla-
tion coefficients for the initial test administration of the
ITP-PAQ. As expected, the Symptoms, Bother-Physical
Health, Fatigue/Sleep, and Activity scales were moderately
to strongly inter-correlated based on the data from the ini-
tial administration (correlation coefficients ranged from
0.56–0.75; p < 0.05). The Overall QoL scale was moder-
ately to strongly correlated with the other ITP-PAQ scales,
with the exception of the Reproductive Health scale.
In addition to examining the correlations within the ITP-
PAQ scales, construct validity was also assessed by com-
paring the ITP-PAQ scale scores with those of the CES-D
and the SF-36. The CES-D was negatively correlated with
Table 1: Demographic and Clinical Characteristics
Characteristic N = 73
Mean Age 45 years (range, 18–82 years)
Gender
Female 56 (77%)
Male 17 (23%)
Ethnicity/Race
White or Caucasian 61 (84%)
Asian 5 (7%)
Hispanic or Latino 4 (6%)
Black or African American 2 (3%)
American Indian or Alaska Native 1 (1%)
Marital Status
Single, never married 13 (18%)
Married 47 (64 %)
Living with domestic partner/significant other 0 (0%)
Separated 1 (1%)
Divorced 10 (14%)
Widowed 2 (3%)
Education
Less than high school 1 (1%)
High school graduate 13 (18%)
Associate/Technical Degree 13 (18%)
Some college 10 (14%)
Bachelor's degree 18 (25%)
Postgraduate or professional degree 17 (23%)
Medical Insurance
Private insurance 16 (22%)
HMO or PPO 38 (52%)
Medicaid or Medicare 11 (15%)
Other 4 (6%)
No insurance 2 (3%)
Splenectomy (i.e., spleen removed) 42 (58%)
Currently taking medication for ITP 38 (52%)
Ever been transfused with blood or platelets for treatment of 
ITP
37 (52%)
Years since initial Diagnosis of ITP
< 1 year 13 (18%)
1–2 years 10 (14%)
3–4 years 9 (12%)
5–10 years 15 (21%)
> 10 years 26 (36%)Health and Quality of Life Outcomes 2007, 5:11 http://www.hqlo.com/content/5/1/11
Page 6 of 9
(page number not for citation purposes)
all ITP-PAQ scales, except for the Reproductive Health
scale. Other than the Reproductive Health scale, Pearson
correlations ranged from -0.37 to -0.70 (p < 0.05) (data
not shown). Most of the ITP-PAQ scales were moderately
correlated with the SF-36 scales; however, the Reproduc-
tive Health scale was not significantly correlated with any
of the SF-36 scales.
The mean SF-36 scores of the subjects with ITP were com-
pared to those of the general U.S. population norms [15].
Results from t-tests indicate that there were statistically
significant differences (p < 0.05) in SF-36 mean scores
between subjects with ITP (range, 43.04–72.86) and the
general U.S. population (range, 60.86–84.15). Subjects
with ITP reported lower scores on each SF-36 scale com-
pared to the US norm (data not shown).
Known groups validity
Subjects were categorized into two groups according to
gender, splenectomy status, current ITP treatment status,
subject's perception of the effectiveness of ITP treatment,
and time elapsed since ITP diagnosis. When subjects were
grouped according to gender or splenectomy status, no
statistically significant differences were observed for any
of the ITP-PAQ scales (data not shown). Subjects who
were currently receiving treatment for ITP reported lower
scores on all ITP-PAQ scales compared to subjects who
were not currently receiving treatment. Statistically signif-
icant differences (p < 0.01) were reported for the follow-
Table 2: Overview of ITP-PAQ Scales and Item Variability
ITP-PAQ Scales No. of Items Mean Range Example Item
Symptoms 6 3.79 (0.72) 1.86 – 5.00 In the past 4 weeks, how often did you have bleeding episodes (nose 
bleeds, gum bleeds, etc)?
Bother-Physical Health 3 3.62 (1.01) 1.00 – 5.00 Overall, in the past 4 weeks, how bothered have you been by the 
effect of ITP and its treatment(s) on your physical health?
Fatigue/Sleep 4 3044 (1.15) 1.25 – 5.00 In the past 4 weeks, how often did ITP or its treatments cause you 
to feel physically fatigued?
Activity 2 3.55 (1.37) 1.00 – 5.00 In the past 4 weeks, how much has your ITP symptoms or the effects 
of its treatments interfered with your ability to exercise?
Fear 5 4.22 (0.74) 1.50 – 5.00 In the past 4 weeks, how fearful have you been of having a bleeding 
episode (nose bleeds, gum bleeds, etc)?
Psychological Health 5 3.59 (0.98) 1.00 – 5.00 In the past 4 weeks, how often did you have feelings of sadness or 
depression because of your ITP or its treatments?
Work 4 4.13 (0.99) 1.75–5.00 Since you were diagnosed, to what degree has ITP negatively 
interfered with your choice of career(s)?
Social Activity 4 4.26 (0.65) 2.33 – 5.00 In the past 4 weeks, how often has ITP limited your ability to 
participate in social activities?
Women's Reproductive Health 6 3.78 (0.98) 1.00 – 5.00 Thinking about your last period, how bothered were you by: heavier 
bleeding than before having ITP?
Overall QoL 5 3.08 (1.13) 1.00 – 5.00 Overall, in the past 4 weeks, to what extent has ITP and its 
treatment(s) affected your quality of life?
Total 44
Table 3: Test-Retest Reliability (ICCs) and Internal Consistency Reliability (Cronbach's alpha)
Scales ICCs (n = 73)* ICCs (n = 69)† Cronbach's alpha
Symptoms 0.80 0.83 0.71
Fatigue/Sleep 0.87 0.88 0.89
Bother-Physical Health 0.52 0.56 0.79
Activity 0.66 0.66 0.89
Psychological 0.72 0.75 0.92
Fear 0.83 0.87 0.87
Social Activity 0.70 0.74 0.72
Work 0.87 0.87 0.86
Reproductive Health 0.90 0.89 0.66
Overall QoL 0.77 0.81 0.89
*Entire sample
†Sub-sample of respondents who completed the second questionnaire within three weeksHealth and Quality of Life Outcomes 2007, 5:11 http://www.hqlo.com/content/5/1/11
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ing ITP-PAQ scales when subjects were categorized by
treatment status: Symptoms, Fatigue/Sleep, Bother-Physi-
cal Health, Activity, Psychological Health, and Overall
QoL (Figure 1). When subjects were categorized by effec-
tiveness of ITP treatment, statistically significant differ-
ences (p < 0.05) were observed for the Symptoms and
Activity scales (Figure 1), while statistically significant dif-
ferences were only found for the Psychological Health
scale when subjects were categorized according to time
elapsed since ITP diagnosis (data not shown). Subjects
who had been diagnosed with ITP for < 1 year had a lower
mean score on the Psychological Health scale compared
to subjects who had been diagnosed with ITP for at least
one year (50.38 vs. 66.46, respectively; p = 0.02) (data not
shown).
Discussion
The goal of this study was to develop and undertake initial
validation analyses of the ITP-PAQ as a tool for measuring
HRQoL specifically related to adult subjects with ITP. The
results of this study provide preliminary evidence of the
reliability and validity of the ITP-PAQ in this population.
Table 4: Construct Validity as measured by Interscale Pearson Correlations*
Scales S FT B A PH FR SA W RH QoL
Symptoms (S) - 0.67† 0.67† 0.56† 0.60† 0.53† 0.56† 0.39† 0.32 0.50†
Fatigue/Sleep (FT) - 0.75† 0.75† 0.65† 0.54† 0.59† 0.36† 0.19 0.64†
Bother-Physical Health (B) - 0.75† 0.79† 0.56† 0.79† 0.45† 0.08 0.78†
Activity (A) - 0.63† 0.47† 0.62† 0.49† -0.02 0.74†
Psychological (PH) - 0.73† 0.73† 0.60† -0.03 0.76†
Fear (FR) - 0.58† 0.48† 0.07 0.58†
Social Activity (SA) - 0.59† 0.04 0.70†
Work (W) - 0.08 0.66†
Reproductive Health (RH) - 0.13
Overall QoL (QoL) -
† p < 0.05
Known groups validity: Comparison of scale scores by known groups Figure 1
Known groups validity: Comparison of scale scores by known groups. *Statistically significant differences between 
subjects who were currently on treatment and subjects who were not on treatment (p < 0.01). †Statistically significant differ-
ences between subjects who indicated that their treatment was extremely to moderately effective and subjects who indicated 
that their treatment was not effective at all (p < 0.05).
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The results indicate that, with the exception of the Repro-
ductive Health scale, the questionnaire has good internal
consistency. The Reproductive Health scale may not have
reached an acceptable level because the items could in fact
be measuring slightly different concepts. For example, the
Reproductive Health scale includes items that assess
symptom bother related to menstruation in addition to
items that ask how ITP impacts reproductive choices, such
as becoming pregnant, giving birth, and adopting chil-
dren. Perhaps, the symptom bother items in this scale
may fit more appropriately with the Bother-Physical
Health scale, and the reproductive choice items could
comprise a separate scale.
Most of the ITP-PAQ scales also demonstrated acceptable
test-retest reliability, even though the time interval
between test and retest administrations of the question-
naire exceeded the targeted time interval of seven to ten
days. However, two scales, the Bother-Physical Health and
Activity scales, reported ICC values below the acceptable
value of 0.70. In addition to the lag between the two
administrations of the questionnaire, subjects may have
experienced an increase in bother and/or a decrease in
activity due to ITP during the extended time interval.
Additionally, the comparatively low ICC values of the
Bother-Physical Health and Activity scales may be due in
part to the relatively low number of items contained in
each of these scales (four and two items, respectively)
compared to the Symptoms scale which contains six
items.
In general, the construct validity of the questionnaire was
supported by inter-scale correlations. As expected, the
Bother-Physical Health, Symptoms, Fatigue/Sleep, and
Activity scales were more strongly correlated to one
another than with other scales. However, the Reproduc-
tive Health scale had a lower internal consistency reliabil-
ity and it was weakly correlated with the ITP-PAQ scales,
the SF-36, and the CES-D, possibly due to the differing
concepts measured by the items within this scale or the
all-female sample.
Most of the ITP-PAQ scales were moderately correlated
with the SF-36 scales and the CES-D; however, correla-
tions between some of the scales were < 0.40 (e.g., Fear
and SF-36 Mental Health, 0.30; p < 0.05). This low corre-
lation could be due to the ITP-PAQ assessing fear associ-
ated with ITP (e.g., fear of having a bleeding episode),
while the SF-36 provides a more general assessment of
mental health issues (e.g., felt downhearted and blue).
The known-groups validity results indicate that some of
the ITP-PAQ scales (Symptoms, Fatigue/Sleep, Bother-
Physical Health, Activity, Psychological Health, and Over-
all QoL scales) were able to differentiate ITP subjects who
were currently receiving ITP treatment from those who
were not receiving treatment for ITP, providing prelimi-
nary evidence of the ITP-PAQ's ability to distinguish
between groups known to be different. However, the ITP-
PAQ scales were generally unable to distinguish between
subjects when they were grouped by gender, splenectomy
status, perceived effectiveness of treatment and length of
time since ITP diagnosis. The ITP-PAQ may not be able to
differentiate between female and male subjects because
the disorder may affect females and males similarly. Addi-
tionally, significant differences may not have been
observed between subjects who have undergone splenec-
tomy and subjects who have not because 55% of subjects
who had a splenectomy indicated that it did not cure their
ITP. Specifically, the known-groups could be defined as
'subjects without a splenectomy' versus 'subjects with a
failed splenectomy' (for whom QoL likely worsened) ver-
sus 'subjects with a successful splenectomy' (for whom
QoL may have improved). In the future, to assess whether
the ITP-PAQ scales can differentiate between groups of
subjects, it may be worthwhile to categorize subjects by a
more clinically relevant measure, such as platelet count.
Several limitations should be considered when interpret-
ing our findings. Subjects were drawn from a convenience
sample. The study population was fairly homogeneous,
comprised primarily of Caucasian female subjects. The
data was validated using only patient-reported data col-
lected via questionnaire. The lack of clinical data in this
initial validation study will be addressed in on-going piv-
otal trials that will collect clinical data such as platelet
counts and platelet response. In addition, the time inter-
val between the initial and retest administration of the
questionnaire may have been too lengthy to properly
evaluate the test-retest reliability. Because 25% of subjects
did not complete the questionnaire within the targeted fif-
teen day interval, those subjects may have undergone clin-
ical changes that may have affected their responses. In
future validation studies platelet counts or type of platelet
response should be used to identify a stable cohort for the
test-retest analyses. Furthermore, the criteria used to cate-
gorize the subjects for the known groups validity evalua-
tion may not have been sufficient to allow for the ITP-
PAQ scales to detect differences between groups. Group-
ing the subjects by a different criterion, such as a relevant
clinical measure, may bolster the findings for its known
groups validity.
Conclusion
The primary goal of this manuscript was to describe the
development of a new ITP-specific HRQoL questionnaire
for adults with ITP and to present our initial findings on
the psychometric properties of this questionnaire. The
results of this initial validation study indicate that the
questionnaire generally has acceptable reliability andHealth and Quality of Life Outcomes 2007, 5:11 http://www.hqlo.com/content/5/1/11
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validity. We plan to conduct additional analyses using
more objective clinical measures such as platelet counts as
a criterion for known groups validity. Further validation
work should also be conducted to assess its responsive-
ness and to estimate its minimal clinical important differ-
ence value so that it can become a more widely used
HRQoL measure in the ITP population.
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